Ticker News
$DCOY News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
Decoy (DCOY) expands IP to cover D‐MAVs, manufacturing and IMP3ACT design platform
Decoy Therapeutics (NASDAQ: DCOY) expanded its intellectual property portfolio to seven patent families with one granted U.S. patent and 19 pending applications across seven jurisdictions, covering antiviral peptide conjugates, manufacturing methods, formulations and the IMP3ACT design platform. The granted U.S. patent (No. 12,226,474) claims antiviral peptide conjugates with D‐amino acid viral spike sequences, and a June 2026 filing covers the platform's design methods—strengthening proprietary protection for its Designable Multi‐Antivirals while most applications remain pending.
Decoy Therapeutics (DCOY) elects ex‐Moderna leader Patricia Gauthier to board
Decoy Therapeutics (NASDAQ: DCOY) said stockholders elected Patricia Gauthier, former Moderna SVP and ex‐GSK leader, as a Class II director at its July 14, 2026 annual meeting. The company says her commercialization, manufacturing and market‐access experience will help advance Decoy's Designable Multi‐Antiviral (D‐MAV) programs toward the clinic.
DCOY private placement: initial ~$3.5M, up to ~$21M via milestone-tied warrant exercises
Decoy Therapeutics (DCOY) announced a private placement with a healthcare-focused institutional investor that could provide up to approximately $21M total: an expected initial closing of about $3.5M in gross proceeds and additional funding tied to milestone-based warrant exercises. Initial dilution will occur at the initial closing (≈$3.5M); further dilution is contingent on specified clinical and regulatory milestones (European CTA, UK Phase 2a approval, positive human challenge data) and related warrant issuance/exercise. Timing: Same-day dilution is possible only if the company starts sales under the facility, and the press release does not say when that could happen.
DCOY inks private placement up to ~$21M; initial close ~ $3.5M, milestone warrants
Decoy Therapeutics (DCOY) announced a private placement with a healthcare-focused institutional investor that could deliver up to approximately $21 million via upfront proceeds plus milestone-tied warrant exercises. The initial closing is expected to generate about $3.5 million in gross proceeds and additional tranches hinge on regulatory/clinical milestones (EU clinical trial authorization, UK Phase 2a approval, positive human challenge data), so further dilution is conditional on those triggers. Timing: Same-day dilution is possible only if the company starts sales under the facility, and the press release does not say when that could happen.
DCOY CEO to speak at hVIVO Capital Markets Day in London
Decoy Therapeutics (DCOY) said CEO Rick Pierce will speak at hVIVO's Capital Markets Day in London on June 11 to discuss early clinical development and the strategic value of human challenge trials. The company reiterated its AI-enabled IMP3ACT platform and a pan-coronavirus D-MAV program targeting clinic entry in 2027 — the update raises investor visibility but includes no new clinical data or filings.
Decoy (DCOY) partners with hVIVO to advance lead D‐MAV toward Phase 1/2a and human challenge studies
Decoy Therapeutics (DCOY) has engaged hVIVO to support translational modeling, regulatory strategy, CMC/nonclinical consulting and preparation for Phase 1 first‐in‐human and Phase 2a proof‐of‐concept studies for its lead D‐MAV respiratory antiviral, with planned regulatory interactions in the EU/UK and intent to pursue US registration. hVIVO's human challenge trial expertise and facilities are expected to inform dose selection and study design and create a repeatable clinical template for Decoy's D‐MAV portfolio, but the program is still preclinical and no IND/CTA has been filed.